Compares a trial medicine, MK-8748, with aflibercept for diabetic macular edema
Tests MK-8748 against aflibercept in adults with diabetic macular edema.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Mladá Boleslav, Náchod, Pardubice V, Prague, and Prague 5, CzechiaSee the 7 sitesAlso in 10 other countries, 90 sites
- Trial code
- NCT07705555
- EU 2026-526790-42-01
- 2026-526790-42-00
- U1111-1340-0203
- Registry title
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 960 people, planned
- Started
- 27 Aug 2026
- Expected to end
- 31 Oct 2029
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MK-8748
- Aflibercept
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 or type 2 diabetes whose vision has dropped mainly because of diabetic macular edema (swelling in the centre of the retina).
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Diabetic macular edema in the study eye, causing a decrease in vision. If never treated for it, the diagnosis must be within 9 months of screening. If treated before, the first treatment must be no longer than 3 years before screening.
- Earlier treatment
- People who never had treatment for diabetic macular edema must have been diagnosed within 9 months of screening. People who had treatment must have had their first treatment no longer than 3 years before screening.
- Biomarker or test result
- Hemoglobin A1c (HbA1c) of ≤12% (108 mmol/mol).
Main reasons for not taking part
- Kidney failure needing a kidney transplant or dialysis, or expected to need dialysis during the study
- Stroke or heart attack within 180 days before the first dose
- Newly diagnosed or untreated diabetes with diabetes medicine started within 3 months before the first dose
- Cataract or minimally invasive glaucoma surgery in the study eye within 90 days of screening
- Advanced or uncontrolled glaucoma, past retinal detachment, other active retinal disease in the study eye, or uncontrolled blood pressure
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- The main inclusion criteria include but are not limited to the following:
- Has Type 1 or Type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%
- Has a decrease in vision in the study eye determined by the Investigator to be primarily the result of diabetic macular edema (DME)
- For participants who are treatment-naïve for DME, the diagnosis must have been made within 9 months of screening. For all treatment-experienced participants, the first treatment should have been no longer than 3 years prior to the Screening visit
Who cannot take part
- Has newly diagnosed or previously untreated diabetes mellitus and initiated oral or injectable anti-diabetic medication within 3 months to first dose of study intervention
- Has any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy in the study eye within 90 days of screening
- Has had renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis or has renal failure anticipated to require hemodialysis or peritoneal dialysis at any time during the study
- Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days to first dose of study intervention
- Has history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening
- Has any history of retinal detachment or treatment or surgery for retinal detachment in the study eye
- Has active retinal disease other than the condition under investigation in the study eye
- The main exclusion criteria include but are not limited to the following:
- Has advanced or uncontrolled glaucoma in the study eye
- Has uncontrolled blood pressure at screening
Where in Czechia
Also in 10 other countries, 90 sites
- Oblastni nemocnice Mlada Boleslav, a.s., nemocnice Stredoceskeho krajeMladá Boleslav, CzechiaNot yet recruiting
- VISUS, spol s.r.o.Náchod, CzechiaNot yet recruiting
- Oftex s.r.o.Pardubice V, CzechiaNot yet recruiting
- Astra Clinic.s.r.o.Prague, CzechiaNot yet recruiting
- Fakultni nemocnice Kralovske VinohradyPrague, CzechiaNot yet recruiting
- Vseobecna fakultni nemocnice v PrazePrague, CzechiaNot yet recruiting
- Axon Clinical s.r.o.Prague 5, CzechiaNot yet recruiting
About the trial
What the trial wants to find out
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person.
Read full original descriptionShow less
The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.
The 3 groups in the trial
- MK-8748 Low DoseTreatment being tested
Participants receive 5 initial administrations of MK-8748 low dose every 4 weeks (Q4W), then continue to receive MK-8748 low dose every 8 weeks (Q8W) until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 100.
Treatment: MK-8748
- MK-8748 High DoseTreatment being tested
Participants receive 5 initial administrations of MK-8748 high dose every 4 weeks (Q4W), then continue to receive MK-8748 high dose every 8 weeks (Q8W) until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 100.
Treatment: MK-8748
- Aflibercept 2 mgExisting treatment, for comparison
Participants receive 5 initial administrations of aflibercept 2 mg every 4 weeks (Q4W), then continue to receive aflibercept 2mg every 8 weeks (Q8W) until week 100.
Treatment: Aflibercept
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
- Plain-language title
- Compares a trial medicine, MK-8748, with aflibercept for diabetic macular edemaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 17 November 2026.
- Record updated
- 12 November 2026